Skip Navigation

Sleep, HPA Axis Activity and Paclitaxel-Induced Neuropathic Pain

Sponsored by Oncology Nursing Society Foundation4/1/2009 - 4/1/2011

Sharon L. Kozachik

Sharon L. Kozachik
Principal Investigator

Peripheral neuropathy is a painful and dose-limiting side effect of taxanes, commonly used chemotherapies to treat solid tumor and lymphoid cancers. For the purposes of this study, the taxane paclitaxel is proposed as the vehicle to initiate peripheral neuropathy. Known to occur in as many as 92% of all paclitaxel recipients, this painful neuropathy can reduce quality of life as a consequence of its adverse effects on functioning and ability to perform activities of daily living. 

Meet the Investigators
 

Method

This study employs a 2x2x2 factorial design to determine the roles of sex, HPA axis responsivity, and paclitaxel on sleep architecture changes due to paclitaxel-induced neuropathic pain.

Additional Resources